Keyword: Sanofi

After reporting phase 2b results for FLU-v, SEEK Group CEO Gregory Stoloff said the program is ready for phase 3.

Sanofi's CFO search lasted two months and led the company to a financial executive from French automaker PSA Group.

Another week, another dismal pharma trust and reputation poll. This time, the poll comes from the Reputation Institute.

Why does Sanofi think it can carve a niche in lung cancer when it’ll be sixth to market—and Merck’s Keytruda is far, far ahead?

Recipharm has struck a deal with Sanofi to buy the French drugmaker’s contract inhalation drug business and plant in the U.K.

Drug rebates and list prices have been on a race to the top, and patients pay up. One solution, per HHS chief Alex Azar? Get rid of rebates entirely.

The deal includes a $45 million upfront payment and R&D work in up to five undisclosed infectious disease targets.

GSK and Merck will still lead as the top vaccine makers in 2024, according to a new report, while Sanofi and Pfizer are expected to swap positions.

Sanofi scored plenty of attention with its Twitter pushback against actress Roseanne Barr, but did it boost Sanofi and the Ambien brand?

Sanofi raised the price of Flublok by 12.5% last year, its only increase above the U.S. National Health Expenditure growth rate.